The Use of Radiolabelled Anticancer Drugs in Phase I/II Clinical Trials and the Assessment of Therapeutic Efficacy of New Agents Using PET-Reference-Cited by-同舟云学术

The Use of Radiolabelled Anticancer Drugs in Phase I/II Clinical Trials and the Assessment of Therapeutic Efficacy of New Agents Using PET

Published:1995 Issue: Volume: Page:301-326
ISSN:
Container-title:PET for Drug Development and Evaluation
language:
Short-container-title:

Author:

Price Pat,Harte Robert,Tilsley Owen,Matthews Julian,Brady Frank,Luthra Sajinder,Osman Safiye,Babarovic Robert,Brown Gavin,O’Reilly Susan,Brock Cathryn,Wells Paula,Jones Terry

Publisher

Springer Netherlands

Link

http://link.springer.com/content/pdf/10.1007/978-94-011-0429-6_28.pdf

Reference17 articles.

1. Bignall J. Teaching old drugs new tricks. Lancet 1994; 343: 786.

2. Guttierez AA, Lemoine NT, Sikora K. Gene therapy for cancer, Lancet 1992; 339: 715–21.

3. Price P, Griffiths J. Tumour pharmacokinetics? — we do need to know. The Lancet, 1994; 343: 1174–1175.

4. Financial Times survey. Pharmaceuticals: research and development. Financial Times March 23, 1994

5. Front D, Israel O, Iosilevsky G et al. SPECT quantitation of cobalt-57 bleomycin delivery to human brain tumours. Journal of Nuclear Medicine 1988; 29: 187–194.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is there a future for PET in oncology?;European Journal of Nuclear Medicine;1997-06

2. Future Challenges in the Use of Positron Emission Tomography for In Vivo Molecular Imaging;Impact of Molecular Biology and New Technical Developments in Diagnostic Imaging;1997

3. Drug Development and Positron Emission Tomography;PET for Drug Development and Evaluation;1995